France Makes Medical Cannabis Permanent: What Europe’s Second Legalization Means

From Experimental Pilot to Permanent Law: France’s Two-Year Journey

Published January 15, 2025 — By Ann Karim, Senior Cannabis Editor

The Pilot That Proved France Could Do This

France’s path to a permanent medical cannabis program began with a two-year experimental pilot that enrolled approximately 3,000 patients from March 2021. The pilot was deliberately conservative: only patients with specific conditions who had failed to respond to conventional treatments were eligible, only authorized medical centers could participate, and distribution was strictly controlled. Despite the narrow scope, the pilot generated important safety and efficacy data showing that French patients could access and use cannabis-based medicines safely within a pharmacy-based distribution model. Critically, the pilot demonstrated that France’s existing pharmacy network — one of the largest and most sophisticated in Europe — could handle cannabis products without major systemic disruption. When the pilot concluded in 2024, the French health authorities recommended making the program permanent and significantly expanding eligibility. The January 2025 launch of the permanent program authorized prescriptions for 15 conditions, with distribution through any licensed pharmacy rather than only specialized centers. For French patients, the change was significant: cannabis-based medicines became accessible through the same pharmacist they used for all other prescriptions. See our France cannabis guide for the full current picture on what is and is not legal in France today.

“For my patients with treatment-resistant epilepsy, this is not a political issue. It is a medical one. The pilot showed it works.” — French neurologist, January 2025

What France’s 15 Approved Conditions Cover

France’s permanent medical cannabis program authorizes prescriptions for a defined list of 15 conditions where clinical evidence supports benefit and where patients have not responded adequately to conventional treatments. The primary conditions include chronic neuropathic pain, chemotherapy-induced nausea and pain, epilepsy refractory to standard treatments, spasticity associated with multiple sclerosis, and palliative care. The pharmacy-only model means patients go through a familiar institutional channel: see an authorized specialist, receive a prescription, fill it at any licensed pharmacy. Products are standardized pharmaceutical preparations, not the flower-dominant range seen in Canada or Germany. THC content in French-approved products is carefully controlled, and all products must pass pharmaceutical manufacturing standards. The 300,000 patient target reflects the estimated eligible population across all 15 conditions in France’s 60 million-plus population. For context, Australia, with a population of 26 million, had already exceeded 1.5 million prescriptions by 2023 — suggesting France’s conservative patient targeting may prove too low if doctors and patients adopt the program enthusiastically. The medical cannabis guide covers France alongside all major medical programs globally.

France’s Conservative Stance on Recreational Cannabis

Despite the medical program’s expansion, France remains one of Europe’s most resistant major nations to recreational cannabis legalization. The country has some of Europe’s highest rates of cannabis consumption despite strict prohibition, and enforcement has historically been applied unevenly across socioeconomic and ethnic lines — a reality that reform advocates frequently cite. However, the French political landscape does not currently support recreational legalization: both Macron’s centrist bloc and the major opposition parties have refused to make legalization a platform position. The contrast with neighboring Germany’s adult-use legalization could not be sharper: two of Europe’s largest nations have taken radically different approaches within a few years of each other. Reform advocates in France argue that the success of the medical program will shift public and political opinion over time, pointing to how medical legalization in the US consistently preceded recreational reform by years. For travelers visiting France, cannabis possession remains a criminal offence regardless of the medical program, and our cannabis laws database makes this clear.

The European Ripple Effect: What France’s Permanent Program Signals

France’s decision to make medical cannabis permanent, following Germany’s adult-use legalization and the Dutch wiet experiment, is another data point in an accelerating European reform trend. With France — historically among the most conservative large EU states on drug policy — now operating a permanent medical program, the political space for reform across the continent has expanded measurably. Countries like Italy, Spain, and Poland, which have had internal medical cannabis debates for years, can no longer point to France as a European holdout justifying their own inaction. The European Medicines Agency and national health ministries across the EU are watching France’s pharmacy-distribution model closely as a potential template. Our cannabis travel guide and the drug test calculator remain essential tools for anyone navigating Europe’s rapidly evolving cannabis landscape — and for French patients newly accessing legal medicine, the calculator helps understand workplace testing implications before beginning treatment.